In conclusion, our study reveals a complex interplay among HCC, HCV, and PCSK9 plasma levels confirming the potent inducing activity of HCV on PCSK9, particularly the G2 phenotype, even in patients with significant liver impairment, such as those with HCC. This evidence concerns the gene PCSK9 and hepatocellular carcinoma.